Ascletis submits an FDA IND for ASC30_39 FDC, combining oral GLP-1 and amylin receptor agonists, supported by promising preclinical and pharmacokinetic findings.
Written By: Aabha Dey, BPharm
Reviewed By: Pharmacally Editorial Team
Ascletis Pharma has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for ASC30_39 FDC, a once-daily oral fixed-dose combination of two small-molecule drugs, ASC30 and ASC39. The formulation brings together a glucagon-like peptide-1 receptor (GLP-1R) agonist and a selective amylin receptor agonist, targeting two complementary pathways involved in appetite and body-weight regulation.
Announced on November 11, 2026, the submission represents a regulatory milestone for the company’s obesity pipeline. According to Ascletis, ASC30_39 FDC is the first co-formulation of an oral GLP-1 agonist and an oral amylin agonist to reach the IND submission stage. Its development is supported by preclinical pharmacology, animal efficacy and formulation pharmacokinetic findings, although human safety and efficacy data for the combination are not yet available.
ASC39 Shows Selectivity Towards the Amylin Receptor
ASC39 is an oral small-molecule amylin receptor agonist. Amylin, a hormone released by the pancreas after meals, contributes to appetite regulation and satiety.
In a head-to-head cyclic adenosine monophosphate (cAMP) activation assay, ASC39 demonstrated an EC50 of 21.4 pM at the human amylin 1 receptor (hAMY1R), compared with 846.1 pM at the human calcitonin receptor (hCTR). This represents approximately 40-fold selectivity towards hAMY1R.
The findings were comparable to eloralintide, which demonstrated EC50 values of 21.2 pM and 1,350.8 pM at hAMY1R and hCTR, respectively, corresponding to approximately 64-fold selectivity. These results support ASC39’s receptor-selective pharmacological profile, although they do not establish clinical efficacy or tolerability.
ASC39 Produces Weight Reduction in Preclinical Rat Studies
Ascletis evaluated ASC39 monotherapy in diet-induced obese (DIO) rats. Animals received oral ASC39 at 5 mg/kg once daily for six consecutive days, with outcomes compared against vehicle-treated animals and an eloralintide group.
ASC39-treated animals demonstrated a 6.0% reduction in body weight from baseline, compared with a 0.6% increase in the vehicle group, resulting in a placebo-adjusted weight reduction of 6.6%. Eloralintide produced a 5.0% reduction from baseline and a 5.6% placebo-adjusted reduction. The difference between ASC39 and vehicle was statistically significant (p<0.0001).
However, ASC39 was administered orally once daily, whereas eloralintide was administered subcutaneously once every three days at 3 nmol/kg. The six-day animal study therefore provides an early efficacy signal rather than evidence of superiority or comparable effectiveness in humans. Importantly, these weight-reduction findings relate to ASC39 monotherapy, not ASC30_39 FDC.
Combining GLP-1 and Amylin Activity in One Oral Formulation
GLP-1 receptor activation influences appetite, food intake, glucose regulation and gastric emptying, while amylin contributes to satiety and meal-related appetite control. Combining these pathways is intended to address weight regulation through complementary pharmacological mechanisms rather than relying on GLP-1 activity alone.
Ascletis developed ASC30_39 FDC using its proprietary formulation technology. The company reported good compatibility between the two ingredients, room-temperature stability and a relatively small tablet size.
The fixed-dose combination also demonstrated favourable pharmacokinetic properties in dogs following oral administration. ASC30_39 FDC showed excellent oral bioavailability, high drug exposure and a half-life of up to 12 hours. These pharmacokinetic parameters were consistent with those observed for the respective monotherapies in a head-to-head dog study. The findings support the feasibility of combining both compounds in a once-daily oral formulation, although human pharmacokinetics remain to be established.
ASC30 Already Undergoing Phase III Evaluation
The development of ASC30_39 FDC builds on the clinical progress of ASC30 as a standalone treatment. ASC30 is currently being evaluated in two global Phase III studies, AURORA-1 and AURORA-2, involving approximately 4,600 participants with obesity or overweight across the United States, Europe and Canada. Ascletis expects topline results from the programme in the third quarter of 2028.
Ascletis has also submitted a separate IND application for ASC39 monotherapy, announced on October 25, 2026. The company anticipated initiating a Phase I study in the fourth quarter of 2026.
Clinical Context: From Preclinical Evidence to Human Evaluation
The ASC30_39 FDC IND submission brings together two orally administered small molecules with distinct but complementary metabolic targets. The development programme has established early evidence of receptor selectivity for ASC39, weight reduction in obese rats with ASC39 monotherapy, and favourable pharmacokinetic and formulation characteristics for the combination.
However, these findings address different stages of development and should not be interpreted collectively as proof of combination efficacy. The dog pharmacokinetic study supports oral delivery, while the rat study provides an efficacy signal for ASC39 alone. Neither establishes the effectiveness or safety of ASC30_39 FDC in humans.
The next important step will be to determine whether the combination maintains suitable exposure and tolerability in human studies and whether simultaneous GLP-1 and amylin receptor activation produces a meaningful advantage over either approach individually. Its clinical value will ultimately depend on demonstrating sustained weight reduction, an acceptable safety profile and a practical dosing regimen.
For now, ASC30_39 FDC represents an additional development approach in the expanding pipeline of oral obesity treatments. Its progression into clinical evaluation will determine whether the preclinical rationale translates into a clinically meaningful treatment option.
References
Ascletis Submits IND Application to the U.S. FDA for ASC30_39 FDC, Ascletis Pharma Inc. (November 11, 2026).
About the Writer
Aabha Dey (LinkedIn) is a Pharmacy Bachelor from Delhi Pharmaceutical Sciences and Research University (DIPSAR), New Delhi. She has a strong interest in pharmacology, clinical research and medical writing, with practical exposure through internships in hospital practice, scientific and journal writing, and medical coding. Her academic interests include pharmacovigilance, drug development, regulatory affairs and evidence-based healthcare communication. She is particularly interested in scientific research and translating complex pharmaceutical and clinical information into clear, accurate and accessible content.